BGB-3111,an investigational drug phase 1 clinical study for Cancer treatment is initiated by Beigene , a innovative Oncology company . BGB-3111 is an highly selective , potent inhibitor of Bruton Tyro Kinase (BTK) which is a critical component of B-cell(B-lymphocyte) receptor signalling.
Phase 1a dose escalation part of stud will be performed at fours sites in Australia,which is followed by a phase 1b expansion phase.
BTK is also known as tyrosine-protein kinase BTK . it is an enzyme that is encoded in human beings as "BTK gene".BTK plays crucial role in B-lymphocyte development.
Phase 1a dose escalation part of stud will be performed at fours sites in Australia,which is followed by a phase 1b expansion phase.
BTK is also known as tyrosine-protein kinase BTK . it is an enzyme that is encoded in human beings as "BTK gene".BTK plays crucial role in B-lymphocyte development.